Analytical Quality Control News

FDA Warning Letter: OOS Handling and HPLC Method Validation

When out-of-specification (OOS) laboratory results are explained rather than thoroughly investigated, and HPLC methods are not demonstrably fit for purpose, regulatory action may follow. A recent FDA Warning Letter highlights how recurring weaknesses in OOS handling and analytical method validation can result in significant CGMP compliance risks.

More
Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems

Eurachem has published a new Guide titled The Fitness for Intended Use of Analytical Equipment and Systems – A Laboratory Guide to the Life Cycle of Analytical Equipment and Systems, their Qualification and Related Topics. The document addresses the entire life cycle and qualification of analytical equipment and systems used in laboratories, ranging from simple apparatus to complex computer-based systems, and promotes an integrated, risk-based approach to ensure fitness for intended use.

More
Analytical Quality Group Developments September through December 2025

Find out what the ECA Analytical Quality Control Group was working on and accomplished in the last four months of 2025 - in the latest report.

More
Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing

In Pharmeuropa, the “Comments concerning texts published in Issue 12.3” were published. These include explanations of the new, revised, and corrected texts adopted by the European Pharmacopoeia Commission, including Chapters 2.9.42 and 2.9.43 on dissolution testing.

More
Korean MFDS Publishes Data Collection on Dissolution Test Methods

The Korean Ministry of Food and Drug Safety (MFDS) has published a Dissolution Test Method Data Collection, which includes structured information on dissolution testing, comparisons with major pharmacopoeias, and a checklist for practical use.

More
FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations

The U.S. Food and Drug Administration has issued a Warning Letter to an API manufacturing site in India. Since 2023, approximately 1,500 laboratory incidents (including OOS results and major analytical events) have been recorded, and the authority identified systemic failures in the handling of Out-of-Specification (OOS) results, laboratory investigations, and the overall CAPA system.

More
Questions and Answers on System Suitability Tests (SST) - Part 1

During the ECA Live Online Training “System Suitability Tests (SST) and Troubleshooting for HPLC Methods” on 04 November 2025, a number of interesting and practice-oriented questions were raised by the participants. These questions have been answered in writing by the speakers’ team after the event. To share some of the key insights with a broader audience, we have compiled a selection of these Q&As. Read Part 1 here.

More
PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!

PharmaLab 2025 took place from 24 to 26 November in Neuss, featuring nine parallel conferences and two pre-conference workshops with more than 100 presentations. This year, the ECA Analytical Quality Control Group (AQCG) organised a one-day conference track entitled “Analytical Quality and Lifecycle Concepts”. Moderated by Dr Christopher Burgess (AQCG Chairman), the track comprised a series of presentations and discussions.

More
FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books

Excel spreadsheets remain widely used in GMP-regulated environments, but without adequate controls they pose significant data integrity risks. This news item refers to an FDA Form 483 in which investigators identified fabricated Excel-based production records, deleted electronic files, and duplicate log books, highlighting the importance of robust spreadsheet governance for GMP-compliant data integrity systems.

More
FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory

The U.S. Food and Drug Administration criticises the handling of Out-of-Specification (OOS) results in a recent Warning Letter. Insufficient root cause analyses, premature retesting, and missing effectiveness checks of CAPAs are at the centre of the agency’s concerns. The case once again underlines the regulatory relevance of a robust and scientifically sound OOS management system.

More
x